Related Experiment Video
Updated: Apr 30, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis
Antonietta Notaro1, Selenia Sabella1, Ornella Pellerito2
11. Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Polyclinic, Palermo, Italy.
Abstract:
The synthetic cannabinoid WIN 55,212-2 is a potent cannabinoid receptor agonist with anticancer potential. Experiments were performed to determine the effects of WIN on proliferation, cell cycle distribution, and programmed cell death in human osteosarcoma MG63 and Saos-2 cells. Results show that WIN induced G2/M cell cycle arrest, which was associated with the induction of the main markers of ER stress (GRP78, CHOP and TRB3). In treated cells we also observed the conversion of the cytosolic form of the autophagosome marker LC3-I into LC3-II (the lipidated form located on the autophagosome membrane) and the enhanced incorporation of monodansylcadaverine and acridine orange, two markers of the autophagic compartments such as autolysosomes. WIN also induced morphological effects in MG63 cells consisting in an increase in cell size and a marked cytoplasmic vacuolization. However, WIN effects were not associated with a canonical apoptotic pathway, as demonstrated by the absence of specific features, and only the addition of TRAIL to WIN-treated cells led to apoptotic death probably mediated by up-regulation of the tumor suppressor factor PAR-4, whose levels increased after WIN treatment, and by the translocation of GRP78 on cell surface.
Insights
The synthetic cannabinoid WIN 55,212-2 triggers cell cycle arrest and endoplasmic reticulum stress in osteosarcoma cells. While not inducing apoptosis directly, it primes cells for TRAIL-mediated death, suggesting anticancer potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Synthetic cannabinoids, like WIN 55,212-2, are potent cannabinoid receptor agonists.
- These compounds exhibit potential anticancer properties warranting further investigation.
- Osteosarcoma remains a challenging malignancy with a need for novel therapeutic strategies.
Purpose of the Study:
- To investigate the effects of WIN 55,212-2 on human osteosarcoma cell lines (MG63 and Saos-2).
- To determine the impact of WIN 55,212-2 on cell proliferation, cell cycle distribution, and programmed cell death.
- To elucidate the underlying molecular mechanisms, including endoplasmic reticulum stress and autophagy.
Main Methods:
- Treatment of MG63 and Saos-2 cells with WIN 55,212-2.
- Analysis of cell cycle distribution using flow cytometry.
- Assessment of endoplasmic reticulum stress markers (GRP78, CHOP, TRB3).
- Evaluation of autophagy markers (LC3-I/II conversion, monodansylcadaverine, acridine orange staining).
- Morphological analysis of treated cells.
- Investigation of apoptotic pathways and the role of PAR-4 and TRAIL.
Main Results:
- WIN 55,212-2 induced G2/M cell cycle arrest in osteosarcoma cells.
- Treatment led to the upregulation of endoplasmic reticulum stress markers (GRP78, CHOP, TRB3).
- Evidence of autophagy induction was observed, including LC3-II conversion and autolysosome formation.
- Morphological changes included increased cell size and cytoplasmic vacuolization.
- WIN 55,212-2 did not induce canonical apoptosis but increased PAR-4 levels and GRP78 cell surface translocation.
- Co-treatment with TRAIL enhanced WIN 55,212-2-induced apoptotic death.
Conclusions:
- WIN 55,212-2 exhibits anticancer effects in osteosarcoma cells by inducing cell cycle arrest, ER stress, and autophagy.
- The compound modulates pathways that sensitize cells to TRAIL-induced apoptosis, suggesting a potential therapeutic role.
- Further research into WIN 55,212-2 as a component of osteosarcoma treatment is warranted.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
The Intrinsic Apoptotic Pathway
MAPK Signaling Cascades
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
The Extrinsic Apoptotic Pathway
